Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: IV Non-Hodgkin's lymphoma; Refractory or relapsed follicular lymphoma As monotherapy: 375 mg/m2 via infusion at 50 mg/hr once wkly for 4 doses. May increase rate slowly. If tolerated, may start subsequent infusions at 100 mg/hr and increase slowly. Max rate: 400 mg/hr. W/ cyclophosphamide, vincristine, and prednisolone for follicular lymphoma (CVP) or w/ cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for diffuse large B-cell lymphoma: 375 mg/m2 on day 1 of the chemotherapy cycle after corticosteroid regimen for up to 8 cycles. Patients who were treated w/ 6-8 cycles of CVP chemotherapy and have not progressed: May give 375 mg/m2 once wkly for 4 doses, may repeat 6 mthly up to 16 doses. Maintenance: 375 mg/m2 is given once every 3 mth (patients who have responded to induction chemotherapy) and once every 2 mth (previously untreated patients) until disease progression or a max period of 2 yr. Rheumatoid arthritis Two 1 g infusion doses, separated by 2 wk. Chronic lymphocytic leukaemia 375 mg/m2, given on the day prior to chemotherapy in cycle 1, followed by 500 mg/m2 on day 1 (every 28 days) of cycles 2-6.
Hypersensitivity to murine proteins. Patients w/ active, severe infections. Severely immunocompromised state. Concomitant use w/ live viral vaccines. Lactation.
Special Precautions
Extensive tumour burden, pulmonary insufficiency or pulmonary tumour infiltration; history of cardiac disease. Pregnancy. Monitoring Parameters Monitor CBC and platelet counts regularly and for signs of active infection or hepatitis in hepatitis B carriers. Discontinue therapy if viral hepatitis develops. Cardiac monitoring should be performed during and after all infusions. Preexisting pulmonary conditions should be closely monitored for possible infusion-related toxicity. Monitor renal function.
Adverse Reactions
Reactivation of hepatitis B virus. Fever and rigors. Pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, asthenia, headache, rhinitis, thrombocytopenia, neutropenia, anaemia, abdominal pain, bowel obstruction, and perforation. Exacerbation of heart failure and angina pectoris. Reversible interstitial pneumonia and interstitial fibrosis. Depletion of immunoglobulin concentrations.
Potentially Fatal: Toxic epidermal necrolysis and Stevens-Johnsons syndrome. Pulmonary or cardiac toxicity during infusion; severe mucocutaneous reactions; severe cytokine release syndrome associated w/ tumour lysis syndrome. Myocardial infarction, ventricular fibrillation, and cardiogenic shock. Increased risk of progressive multifocal leukoencephalopathy. Paraneoplastic pemphigus.
Drug Interactions
Increased risk of renal toxicity w/ cisplatin.
ATC Classification
L01XC02 - rituximab ; Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
Disclaimer: This information is independently developed by CIMS based on rituximab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in